Skip to main content

Proof of concept and pre-commercialisation of personalised liquid biopsies in cancer therapy

Project description

Novel high-sensitivity liquid biopsy in cancer therapy

The analysis of cancer biomarkers during the follow-up of the treatment and in the postoperative period requires high sensitivity. The EU-funded BiopSense project is developing a novel technology that allows very sensitive detection of single-nucleotide polymorphism in the samples, enabling point-of-care screening of liquid biopsies. This diagnostics platform will represent an open system that can accommodate the design of new diagnostic targets. The technology is based on a patented invention and will include features for automated sample preparation and lab-on-chip design. The project objectives include verification of the complete platform components and establishment of the sensitivity and accuracy of the chemistry for evaluation against a competitive mass spectrometry platform.

Host institution

JYVASKYLAN YLIOPISTO
Net EU contribution
€ 149 999,99
Address
Seminaarinkatu 15
40100 Jyvaskyla
Finland

See on map

Region
Manner-Suomi Länsi-Suomi Keski-Suomi
Activity type
Higher or Secondary Education Establishments
Other funding
€ 149 999,99

Beneficiaries (1)

JYVASKYLAN YLIOPISTO
Finland
Net EU contribution
€ 149 999,99
Address
Seminaarinkatu 15
40100 Jyvaskyla

See on map

Region
Manner-Suomi Länsi-Suomi Keski-Suomi
Activity type
Higher or Secondary Education Establishments
Other funding
€ 149 999,99